Treatment Outcome and Prognosis Factors of FIGO 2018 Stage III Cervical Cancer Patients Treated with Definitive Concurrent Chemoradiation in Vietnam

Document Type : Research Articles

Authors

1 Department of Medical Oncology 6, Vietnam National Cancer Hospital, Hanoi, Vietnam.

2 Department of Oncology, Vietnam University of Traditional Medicine, Hanoi, Vietnam.

3 Department of Oncology, Hanoi Medical University, Hanoi, Vietnam.

4 Department of Breast and Gynecologic Radiotherapy, Vietnam National Cancer Hospital, Hanoi, Vietnam.

5 Department of Medical Oncology 2, Vietnam National Cancer Hospital, Hanoi, Vietnam.

Abstract

Objective: This study aimed to analyze the treatment outcome and toxicities, along with prognosis factors of patients with FIGO 2018 stage III cervical cancer treated with definitive concurrent chemoradiation. Methods: A total of 83 stage III cervical cancer patients with good performance status (ECOG PS 0, 1) were treated with three-dimensional conformal radiation therapy (3D-CRT) combined with chemotherapy (weekly cisplatin), followed by high-dose-rate (HDR) brachytherapy between January 2017 and March 2019 at Vietnam National Cancer hospital. Treatment outcomes and prognosis factors were assessed along with acute and late toxicities. Results: The 3-year DFS was 67.8% and 3-year OS was 80.3%. On multivariate analyses, short axis of pelvic lymph node diameter of ≥ 15mm, invasion of the lower third of vagina and para-aortic lymph node metastasis were identified as adverse prognostic factors for DFS. The cumulative incidence rate of gastrointestinal and genitourinary toxicity (≥ grade 2) at the 3-year follow-up were 29.6% and 11.6%, respectively. Conclusions: 3D CRT and HDR brachytherapy with concurrent chemotherapy is an effective treatment, with acceptable toxicity for FIGO 2018 stage III cervical cancer in Vietnam.
 

Keywords

Main Subjects

Asian Pacific Journal of Cancer Prevention
Volume 22, Issue 3
March 2021
Pages 853-859

Files

History

  • Receive Date: 17 November 2020
  • Revise Date: 20 February 2021
  • Accept Date: 23 March 2021

Share

How to cite

Statistics